Abstracts tagged "Biomarkers"

Abstract Number: 0353 • ACR Convergence 2021
Soluble Urine ALCAM Reflects Renal Disease Activity in Lupus Nephritis
Dalena Chu¹, Noa Schwartz², Jeanette Ampudia¹, Joel Guthridge³, Judith James³, Jill Buyon⁴, Stephen Connelly¹, Maple Fung⁵, Cherie Ng¹, Chandra Mohan⁶ and Chaim Putterman⁷, ¹Equillium, Inc., La Jolla, CA, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴NYU School of Medicine, New York, NY, ⁵Equillium, Inc., San Diego, CA, ⁶University of Houston, Houston, TX, ⁷Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus nephritis (LN) is a leading cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients. While LN pathogenesis has yet to be…
Abstract Number: 0703 • ACR Convergence 2021
CD8 Positron Emission Tomography (PET/CT) Imaging with 89Zr-Df-IAB22M2C in Patients with Inclusion Body Myositis
Colin Quinn¹, Kelsey Moulton¹, Ron Korn², William Le³, Niti Goel⁴, Michael Farwell⁵ and Steven Greenberg⁶, ¹Department of Neurology, University of Pennsylvania, Philadelphia, PA, ²ImaginAb, Inglewood, CA, ³ImaginAb, Inc, Inglewood, CA, ⁴Abcuro, Inc., Newton,, MA, ⁵Department of Radiology, University of Pennsylvania, Philadelphia, PA, ⁶Brigham and Women's Hospital Department of Neurology, Boston, MA
Background/Purpose: Inclusion body myositis (IBM) is a slowly progressive autoimmune skeletal muscle disease for which no effective pharmacological therapy is available. A prominent feature of…
Abstract Number: 1127 • ACR Convergence 2021
Synovial Fluid Cytokines, Chemokines, and MMPs in Osteoarthritis Patients with Knee Pain Compared to RA Patients and Normal Knees
Richard Meehan¹, Elizabeth Regan¹, Eric Hoffman¹, Molly Wolff¹, Mary Gill¹, James Crooks², Presant Parmar³, Richard Scheuring⁴, John Hill⁵, karin Pacheco⁶ and Vijaya Knight⁷, ¹National Jewish Health, Denver, CO, ²National Jewsih Health and Colorado School of Public Health, Denver, CO, ³St Joeseph hospital/NJH, Denver, CO, ⁴NASA/JSC, Houston, TX, ⁵University of Colorado Sports Medicine, Denver, CO, ⁶Nationals Jewish Health, Denver, CO, ⁷Children's Hospital Department of Immunology, Denver, CO
Background/Purpose: A major limitation of synovial fluid (SF) biomarker studies in osteoarthritis (OA) has been difficulty in obtaining SF (SF) in patients with small effusions.…
Abstract Number: 1301 • ACR Convergence 2021
Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab
Ioannis Parodis¹, Alvaro Gomez², Julius Lindblom², Alexander Borg², Sharzad Emamikia² and Mariele gatto³, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Department of Rheumatology, University of Padua, Padua, Italy
Background/Purpose: Belimumab blocks soluble B cell activating factor (BAFF) and is the only to date approved targeted treatment for systemic lupus erythematosus (SLE). Identification of…
Abstract Number: 1492 • ACR Convergence 2021
A Permissive Factor of Anti-Ro+ Mothers of Neonatal Lupus Children Is Linked to Overt SLE Associated with Immunity to a Gut Commensal
Robert Clancy¹, Miranda Marion², Hannah Ainsworth², Miao Chang¹, Timothy Howard³, Peter Izmirly⁴, Mala Masson⁵, Jill Buyon⁶ and Carl Langefeld⁷, ¹NYU Grossman School of Medicine, New York, NY, ²Wake Forest University, Winston-Salem, NC, ³Wake Forest University, Quakertown, NC, ⁴New York University School of Medicine, New York, NY, ⁵NYU Grossman School Medicine, New York, NY, ⁶NYU School of Medicine, New York, NY, ⁷Wake Forest University, Winston Salem, NC
Background/Purpose: Unknown factors trigger the transition of anti-Ro+ mothers of neonatal lupus (NL) children from preclinical autoimmunity to clinical disease. One candidate may be the…
Abstract Number: 1937 • ACR Convergence 2021
IL-16 Is Linked to Lupus Nephritis Activity
Andrea Fava¹, Deepak Rao², Chandra Mohan³, Ting Zhang³, Avi Rosenberg¹, Paride Fenaroli⁴, H. Michael Belmont⁵, Peter Izmirly⁶, Robert Clancy⁷, Jose Monroy-Trujillo¹, Derek Fine¹, Arnon Arazi⁸, Celine Berthier⁹, Anne Davidson¹⁰, Judith James¹¹, Betty Diamond¹², Nir Hacohen¹³, David Wofsy¹⁴, Soumya Raychaudhuri², Accelerating Medicines Partership (AMP) RA/SLE Network¹⁵, Jill Buyon⁵, Michelle Petri¹⁶ and The Accelerating Medicines Partnership in RA/SLE¹⁷, ¹Johns Hopkins University, Baltimore, MD, ²Brigham and Women's Hospital, Boston, MA, ³University of Houston, Houston, TX, ⁴Universita` degli Studi di Parma, Parma, Italy, ⁵NYU School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸Feinstein Institutes for Medical Research, Melrose, MA, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Northwell Health, Manhasset, NY, ¹³Broad Institute, Cambridge, MA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Brigham and Women's Hospital, Everett, MA, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Multiple Institutions, Multiple
Background/Purpose: There is a pressing need to identify novel therapeutic targets in lupus nephritis. Multiomic approaches hold great potential for discovery. We integrated urine proteomics…
Abstract Number: 0185 • ACR Convergence 2021
Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects
Silke Roedder¹, Emily Wendt², Chad Burris², Jonathan Nazareon², Grace Park³, Phil Pangilinan², Gianna Huang², Anubhav Mathur², James Taylor², Andrew Billin² and Franziska Matzkies⁴, ¹Gilead Sciences, Menlo Park, CA, ²Gilead Sciences, Foster City, CA, ³Gilead Sciences, Seattle, WA, ⁴Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of autoimmune diseases including Rheumatoid Arthritis (RA) and Lupus Erythematosus (LE). Immune complexes…
Abstract Number: 0384 • ACR Convergence 2021
A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in Spondyloarthritis: The Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio
Rouhin Sen¹, Emmeline Kim², Elizabeth Cheng³, Kavya Ganuthula⁴, Meika Fang⁵, Gail Kerr⁶, Jessica Walsh⁷, Elizabeth Chang⁸, Siba Raychaudhuri⁹, Andreas Reimold¹⁰ and Liron Caplan¹¹, ¹University of Colorado School of Medicine/Rocky Mountain Regional Veterans Affairs Medical Center (VAMC), Denver, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Rocky Mountain Regional VAMC, Aurora, CO, ⁴Rocky Mountain Regional VAMC/University of Colorado School of Medicine, Aurora, CO, ⁵David Geffen School of Medicine at UCLA/West Los Angeles Veterans Affairs Medical Center (VAMC), Los Angeles, CA, ⁶Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁷Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁸Phoenix Veterans Affairs Medical Center (VAMC), Phoenix, AZ, ⁹Sacramento Veterans Affairs Medical Center (VAMC)/University of California-Davis Health, Davis, CA, ¹⁰University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ¹¹Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Biomarkers of disease activity/severity and imaging outcomes in axial spondyloarthritis (axSpA) remain a challenge. The most common relevant biomarker is the C-Reactive Protein (CRP),…
Abstract Number: 0788 • ACR Convergence 2021
Red Cell Distribution Width Is Associated with Baseline 25-hydroxyvitamin D Level Before Methotrexate Therapy in Rheumatoid Arthritis
Shahdi Malakooti¹, Brigid Wilson², Taissa Bej², Lenche Kostadinova³, Alyssa Lange², Megan O'Mara², David Zidar², Maya Mattar⁴ and Donald Anthony⁵, ¹Case Western Reserve University, UH Cleveland Medical Center, VA Medical Center, Cleveland, OH, ²VA Medical Center, Cleveland, OH, ³UH Cleveland Medical Center, VA Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Mayfield Heights, OH, ⁵Case, VA, Metro, Chardon, OH
Background/Purpose: Peripheral blood red cell distribution width (RDW) correlates with disease activity in rheumatoid arthritis (RA) and is associated with subsequent mortality in non-RA patient…
Abstract Number: 1128 • ACR Convergence 2021
Inter-relationships Between Multiple Joint Osteoarthritis and Collagen Biomarkers in Men: The Johnston County Osteoarthritis Project
Amanda Nelson¹, Liubov Arbeeva¹, Duncan Lascelles², Jordan Renner¹, Yvonne Golightly¹, Morten Karsdal³, Anne-Christine Bay-Jensen³ and Richard Loeser⁴, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²North Carolina State University, Raleigh, NC, ³Nordic Bioscience, Herlev, Denmark, ⁴University of North Carolina, Chapel Hill, NC
Background/Purpose: To determine inter-relationships between blood-based collagen formation and degradation biomarkers and multiple joint osteoarthritis (MJOA) phenotypes in a community-based cohort.Methods: Data were from Johnston…
Abstract Number: 1303 • ACR Convergence 2021
Associations Between Early Changes in Circulating B Cell Subsets and Severe Flare in Systemic Lupus Erythematosus – Results from Three Phase III Trials of Belimumab
Ioannis Parodis¹, Alvaro Gomez², Julius Lindblom², Alexander Borg², Sharzad Emamikia² and Mariele gatto³, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Department of Rheumatology, University of Padua, Padua, Italy
Background/Purpose: Belimumab is the only approved targeted treatment for systemic lupus erythematosus (SLE). Identification of early predictors of response or non-response to therapy is imperative…
Abstract Number: 1520 • ACR Convergence 2021
Do Specific Rheumatic Autoantibodies Predict Severity or Time to Onset of Immune-related Adverse Events from Checkpoint Inhibitors?
Nilasha Ghosh¹, Deanna Jannat-Khah², Karmela Kim Chan², Michael Postow³ and Anne Bass⁴, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Memorial Sloane Kettering Cancer Center, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) are a novel cancer therapeutic that have had a dramatic impact on treating advanced malignancies by enhancing the anti-tumor T…
Abstract Number: 0213 • ACR Convergence 2021
Quantitative Assessment of Volumetric Change in Hip Effusion Using Artificial Intelligence in Patients with Osteoarthritis of the Hip
Jacob Jaremko¹, Banafshe Felfeliyan², Abhilash Hareendranathan¹, Bashiar Thejeel¹, Vanessa Quinn-Laurin¹, Mikkel Ostergaard³, Philip Conaghan⁴, Robert Lambert¹, Janet Ronsky² and Walter Maksymowych¹, ¹University of Alberta, Edmonton, AB, Canada, ²University of Calgary, Calgary, AB, Canada, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Accurate quantification of hip effusion volume may aid effective OA management as synovitis of the hip has been associated with pain and structural damage…
Abstract Number: 0395 • ACR Convergence 2021
RNA Polymerase III Autoantibody Levels and Risk of Systemic Sclerosis in Patients with Raynaud Phenomenon
Megan Lockwood¹, Yuqing Zhang², Marcy Bolster¹, Sara Schoenfeld¹, Xiaoqing Fu¹, Seth Brownmiller¹, Ana Fernandes¹ and Flavia Castelino¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA
Background/Purpose: Raynaud phenomenon is often the initial manifestation in systemic sclerosis (SSc) and can precede other SSc symptoms by years (1). Several SSc-specific autoantibodies are…
Abstract Number: 0790 • ACR Convergence 2021
Unraveling Heterogeneity Within ACPA-negative Rheumatoid Arthritis; The Subgroup of Patients with a Strong Clinical and Serological Response to Initiation of DMARD-treatment Favor Disease Resolution
Marloes Verstappen¹, Hanna van Steenbergen², Pascal de Jong³ and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden Univeristy Medical Center, Leiden, Netherlands, ³Erasmus MC, Hendrik Ido Ambacht, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a heterogeneous disease, especially ACPA-negative-RA. This is reflected by differences in long-term outcomes, ranging from refractory RA to sustained-DMARD-free-remission(SDFR; sustained…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].